Since interleukin 23 (IL-23) has been shown to sustain CRC progression [279], a further trial on the high-risk group of FAP patients was conducted using guselkumab, an anti-IL-23 monoclonal antibody. The gene discussed is IL37; the disease is colorectal carcinoma.